Efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases: A systematic review and meta-analysis.
- Author:
Li YANG
1
;
Bo FANG
2
;
Can-Qin HE
2
;
Xu-Xin ZHAN
3
;
You-Ping XIAO
1
;
Xiao-Jun QIN
1
;
Qiang LOU
1
;
Xue-Jun SHANG
2
Author Information
1. Department of Orthopaedics, The Second Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang, Guizhou 550001, China.
2. Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210002, China.
3. Department of Reproductive Medicine, Xi'an Peoples' Hospital /Xi'an Fourth Hospital, Xi'an，Shaanxi 710004,China.
- Publication Type:English Abstract
- Keywords:
denosumab;
prostate cancer with bone metastasis;
meta-analysis;
systematic review;
randomized controlled trial
- MeSH:
Humans;
Denosumab/therapeutic use*;
Bone Neoplasms/drug therapy*;
Prostatic Neoplasms/drug therapy*;
Male;
Randomized Controlled Trials as Topic;
Bone Density Conservation Agents/therapeutic use*
- From:
National Journal of Andrology
2025;31(4):349-356
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases.
METHODS:Relevant studies were retrieved from PubMed, EMBASE, Cochrane, Web of Science, Sinomed , CNKI and Wanfang databases. The Cochrane risk-of-bias assessment tool was used to evaluate the quality of included studies, and relevant data were extracted. meta-analysis was performed using RevMan 5.4 and RStudio software, and forest plots were generated.
RESULTS:Six randomized controlled trials (RCTs) were included. Compared with the control group, denosumab significantly reduced the risk of skeletal-related events (HR=0.78, 95% CI: 0.62-0.93). In terms of safety, denosumab did not increase the risk of total adverse events, severe adverse events and the adverse events higher than CTC grade 3.
CONCLUSION:Denosumab can delay the time to first skeletal-related event with good safety. However, due to the limitations of this study, further high-quality, large-sample, multicenter RCTs are needed to confirm these findings.
